Personalized symptom management: a quality improvement collaborative for implementation of patient reported outcomes (PROs) in 'real-world' oncology multisite practices.

Cancer Health care utilization Multisite Oncology practices Patient reported outcomes QI collaborative Real world implementation

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
17 Jun 2020
Historique:
received: 02 03 2020
accepted: 04 06 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 20 6 2020
Statut: epublish

Résumé

Little research has focused on implementation of electronic Patient Reported Outcomes (e-PROs) for meaningful use in patient management in 'real-world' oncology practices. Our quality improvement collaborative used multi-faceted implementation strategies including audit and feedback, disease-site champions and practice coaching, core training of clinicians in a person-centered clinical method for use of e-PROs in shared treatment planning and patient activation, ongoing educational outreach and shared collaborative learnings to facilitate integration of e-PROs data in multi-sites in Ontario and Quebec, Canada for personalized management of generic and targeted symptoms of pain, fatigue, and emotional distress (depression, anxiety). We used a mixed-methods (qualitative and quantitative data) program evaluation design to assess process/implementation outcomes including e-PROs completion rates, acceptability/use from the perspective of patients/clinicians, and patient experience (surveys, qualitative focus groups). We secondarily explored impact on symptom severity, patient activation and healthcare utilization (Ontario sites only) comparing a pre/post population cohort not exposed/exposed to our implementation intervention using Mann Whitney U tests. We hypothesized that the iPEHOC intervention would result in a reduction in symptom severity, healthcare utilization, and higher patient activation. We also identified key implementation strategies that sites perceived as most valuable to uptake and any barriers. Over 6000 patients completed e-PROs, with sites reaching 51%-95% population completion rates depending on initial readiness. e-PROs were acceptable to patients for communicating symptoms (76%) and by clinicians for treatment planning (80%). Patient experience was better than the provincial average. Compared to the pre-population, we observed a significant reduction in levels of anxiety (p = 0.008), higher levels of patient activation (p = 0.045), and reduced hospitalization rates (12.3% not exposed vs 10.1% exposed, p = 0.034). A pre/post population trend towards significance for reduced emergency department visit rates (14.8% not exposed vs 12.8% exposed, p = 0.081) was also noted. This large-scale pragmatic quality improvement project demonstrates the impact of implementation strategies and a collaborative improvement approach on acceptability of using PROs in clinical practice and their potential for reducing anxiety and healthcare utilization; and improving patient experience and patient activation when implemented in 'real-world' multi-site oncology practices.

Sections du résumé

BACKGROUND BACKGROUND
Little research has focused on implementation of electronic Patient Reported Outcomes (e-PROs) for meaningful use in patient management in 'real-world' oncology practices. Our quality improvement collaborative used multi-faceted implementation strategies including audit and feedback, disease-site champions and practice coaching, core training of clinicians in a person-centered clinical method for use of e-PROs in shared treatment planning and patient activation, ongoing educational outreach and shared collaborative learnings to facilitate integration of e-PROs data in multi-sites in Ontario and Quebec, Canada for personalized management of generic and targeted symptoms of pain, fatigue, and emotional distress (depression, anxiety).
PATIENTS AND METHODS METHODS
We used a mixed-methods (qualitative and quantitative data) program evaluation design to assess process/implementation outcomes including e-PROs completion rates, acceptability/use from the perspective of patients/clinicians, and patient experience (surveys, qualitative focus groups). We secondarily explored impact on symptom severity, patient activation and healthcare utilization (Ontario sites only) comparing a pre/post population cohort not exposed/exposed to our implementation intervention using Mann Whitney U tests. We hypothesized that the iPEHOC intervention would result in a reduction in symptom severity, healthcare utilization, and higher patient activation. We also identified key implementation strategies that sites perceived as most valuable to uptake and any barriers.
RESULTS RESULTS
Over 6000 patients completed e-PROs, with sites reaching 51%-95% population completion rates depending on initial readiness. e-PROs were acceptable to patients for communicating symptoms (76%) and by clinicians for treatment planning (80%). Patient experience was better than the provincial average. Compared to the pre-population, we observed a significant reduction in levels of anxiety (p = 0.008), higher levels of patient activation (p = 0.045), and reduced hospitalization rates (12.3% not exposed vs 10.1% exposed, p = 0.034). A pre/post population trend towards significance for reduced emergency department visit rates (14.8% not exposed vs 12.8% exposed, p = 0.081) was also noted.
CONCLUSION CONCLUSIONS
This large-scale pragmatic quality improvement project demonstrates the impact of implementation strategies and a collaborative improvement approach on acceptability of using PROs in clinical practice and their potential for reducing anxiety and healthcare utilization; and improving patient experience and patient activation when implemented in 'real-world' multi-site oncology practices.

Identifiants

pubmed: 32556794
doi: 10.1186/s41687-020-00212-x
pii: 10.1186/s41687-020-00212-x
pmc: PMC7300168
doi:

Types de publication

Journal Article

Langues

eng

Pagination

47

Subventions

Organisme : Canadian Partnership Against Cancer
ID : 0

Investigateurs

Katherine George (K)
Zahra Ismail (Z)
Adriana Krasteva (A)
Ashley Kushneryk (A)
Lorraine Martelli (L)
Alyssa Macedo (A)
Julia Park (J)
Lesley Moody (L)
Lisa Barbera (L)
Pat Giddings (P)
Subhash Bhandari (S)
Linda Tracey (L)
Julie Szasz (J)

Références

Implement Sci. 2009 Jul 14;4:38
pubmed: 19594942
Patient. 2018 Dec;11(6):591-598
pubmed: 29968179
J Oncol Pract. 2014 May;10(3):209-11
pubmed: 24756142
J Oncol Pract. 2014 May;10(3):212-4
pubmed: 24756143
Psychooncology. 2013 Apr;22(4):895-901
pubmed: 22544513
J Oncol Pract. 2012 Nov;8(6):e142-8
pubmed: 23598849
Int J Cancer. 2015 Jul 15;137(2):262-6
pubmed: 24789362
Eur J Cancer Care (Engl). 2013 Jan;22(1):60-9
pubmed: 22694595
Health Qual Life Outcomes. 2019 Oct 16;17(1):156
pubmed: 31619266
Ann Intern Med. 2004 Jun 1;140(11):897-901
pubmed: 15172904
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Support Care Cancer. 2015 Oct;23(10):3025-32
pubmed: 25711657
Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26
pubmed: 15230939
Cochrane Database Syst Rev. 2000;(2):CD000125
pubmed: 10796491
Am Health Drug Benefits. 2012 Jul;5(5):310-7
pubmed: 24991329
Ann Intern Med. 2006 Aug 15;145(4):265-72
pubmed: 16908917
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
Psychooncology. 2011 Jun;20(6):572-84
pubmed: 21442689
Support Care Cancer. 2018 Jan;26(1):41-60
pubmed: 28849277
J Pain Symptom Manage. 2011 Feb;41(2):456-68
pubmed: 20832987
J Natl Cancer Inst. 2014 Oct 07;106(12):
pubmed: 25293984
J Pain Symptom Manage. 2012 Apr;43(4):663-78
pubmed: 22464352
Acta Oncol. 2013 Feb;52(2):216-24
pubmed: 23320770
J Pain Symptom Manage. 2015 Sep;50(3):321-7
pubmed: 25975643
Qual Life Res. 2005 Mar;14(2):373-86
pubmed: 15892426
BMJ. 2013 Jan 28;346:f167
pubmed: 23358487
J Pain Symptom Manage. 2013 Jun;45(6):1083-93
pubmed: 23017617
Fam Pract. 1986 Mar;3(1):24-30
pubmed: 3956899
Implement Sci. 2016 Mar 17;11:38
pubmed: 26988000
Cochrane Database Syst Rev. 2000;(2):CD000409
pubmed: 10796542
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
J Med Ethics. 2018 Mar;44(3):163-164
pubmed: 27538984
N Engl J Med. 2017 Jul 6;377(1):6-9
pubmed: 28679102
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Milbank Q. 2014 Dec;92(4):754-75
pubmed: 25492603
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
J Chronic Dis. 1981;34(12):585-97
pubmed: 7309824
Nat Rev Clin Oncol. 2017 Dec;14(12):763-772
pubmed: 28975931
Soc Sci Med. 2005 Feb;60(4):833-43
pubmed: 15571900
Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134
pubmed: 30231381
J Gen Intern Med. 2012 May;27(5):520-6
pubmed: 22127797
SAGE Open Med. 2018 May 17;6:2050312118773261
pubmed: 29796266
J Oncol Pract. 2017 Aug;13(8):523-529
pubmed: 28692331
Health Psychol. 1995 Mar;14(2):101-8
pubmed: 7789344
J Patient Rep Outcomes. 2018 Dec 27;2(1):64
pubmed: 30588562
Med Care Res Rev. 2012 Apr;69(2):123-57
pubmed: 22203646
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Healthc Pap. 2011;11(4):42-7; discussion 55-8
pubmed: 22543292
Pain. 1983 Oct;17(2):197-210
pubmed: 6646795
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
J Pain Symptom Manage. 2000 Jan;19(1):5-14
pubmed: 10687321
Psychooncology. 2012 Apr;21(4):357-64
pubmed: 21308858
Palliat Support Care. 2014 Feb;12(1):39-51
pubmed: 23942274
BMJ Qual Saf. 2018 Mar;27(3):226-240
pubmed: 29055899
J Contin Educ Health Prof. 2006 Winter;26(1):13-24
pubmed: 16557505
J Oncol Pract. 2016 May;12(5):e513-26
pubmed: 27048610
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
EGEMS (Wash DC). 2015 Oct 29;3(1):1169
pubmed: 26557724
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318

Auteurs

Doris Howell (D)

University Health Network (Princess Margaret Cancer Centre), 610 University Health Network Room 15-617, Toronto, ON, M5G 2M9, Canada. Doris.howell@uhn.ca.
University of Toronto, Toronto, ON, Canada. Doris.howell@uhn.ca.

Zeev Rosberger (Z)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
McGill University, Montreal, Quebec, Canada.

Carole Mayer (C)

Health Sciences North Research Institute, Sudbury, ON, Canada.

Rosanna Faria (R)

Montreal West Island Integrated University Health & Social Services Center, St. Mary's Hospital, Montreal, Quebec, Canada.

Marc Hamel (M)

Psychosocial Oncology Department, McGill University Health Centre, Montreal, Quebec, Canada.

Anne Snider (A)

Juravinski Cancer Centre, Hamilton, ON, Canada.

Denise Bryant Lukosius (DB)

Juravinski Cancer Centre, Hamilton, ON, Canada.
McMaster University, Hamilton, ON, Canada.

Nicole Montgomery (N)

Cancer Care Ontario, Toronto, ON, Canada.

Mindaugas Mozuraitis (M)

Center for Addiction and Mental Health, Toronto, ON, Canada.

Madeline Li (M)

University Health Network (Princess Margaret Cancer Centre), 610 University Health Network Room 15-617, Toronto, ON, M5G 2M9, Canada.
University of Toronto, Toronto, ON, Canada.

Classifications MeSH